Squarepoint Ops LLC Takes $549,000 Position in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Squarepoint Ops LLC purchased a new stake in ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 101,773 shares of the company's stock, valued at approximately $549,000. Squarepoint Ops LLC owned approximately 0.37% of ClearPoint Neuro as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Cubist Systematic Strategies LLC purchased a new position in shares of ClearPoint Neuro during the second quarter valued at approximately $419,000. Point72 DIFC Ltd purchased a new stake in shares of ClearPoint Neuro during the second quarter worth about $32,000. Marshall Wace LLP lifted its holdings in shares of ClearPoint Neuro by 202.2% in the second quarter. Marshall Wace LLP now owns 58,260 shares of the company's stock worth $314,000 after buying an additional 38,984 shares in the last quarter. XTX Topco Ltd lifted its position in shares of ClearPoint Neuro by 11.6% in the second quarter. XTX Topco Ltd now owns 13,010 shares of the company's stock worth $70,000 after buying an additional 1,353 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of ClearPoint Neuro by 562.6% in the 2nd quarter. Renaissance Technologies LLC now owns 169,700 shares of the company's stock valued at $915,000 after acquiring an additional 144,088 shares during the last quarter. 30.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on CLPT shares. B. Riley started coverage on ClearPoint Neuro in a research report on Thursday, July 25th. They set a "buy" rating and a $10.00 price target on the stock. Lake Street Capital boosted their target price on shares of ClearPoint Neuro from $11.00 to $15.00 and gave the company a "buy" rating in a research note on Tuesday, August 27th.

ClearPoint Neuro Price Performance

ClearPoint Neuro stock traded up $0.51 during trading hours on Wednesday, hitting $12.13. The stock had a trading volume of 181,396 shares, compared to its average volume of 177,995. The stock has a market capitalization of $332.60 million, a price-to-earnings ratio of -14.44 and a beta of 1.10. ClearPoint Neuro, Inc. has a 1-year low of $4.05 and a 1-year high of $13.47. The stock's fifty day moving average is $10.96 and its two-hundred day moving average is $7.80.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.03. ClearPoint Neuro had a negative return on equity of 64.23% and a negative net margin of 64.06%. The company had revenue of $7.86 million during the quarter, compared to the consensus estimate of $7.50 million. During the same period last year, the firm earned ($0.29) earnings per share. As a group, sell-side analysts anticipate that ClearPoint Neuro, Inc. will post -0.65 EPS for the current year.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.